Demopulos noted that Omeros retained rights to its MASP-3 small molecule program across multiple therapeutic areas and also retained rights to certain “grandfathered MASP-3 antibodies” with restrictions. The company also entered into a transition services agreement (TSA) to support transfer of the program, with Novo Nordisk reimbursing Omeros for employee costs and other expenses associated with maintaining studies and program operations, as well as reimbursement for inventories of drug substance and drug p ...